Following receipt of the FDA's new Breakthrough Therapy Designation for its investigational cancer compound, ibrutinib, Pharmacyclics Inc., of Sunnyvale, Calif., is gearing up for commercial launch by pricing its public offering of 2.2 million shares of common stock at $94.20 per share, for a total raise of $207.2 million.